BMY Zenbexus: CELMoD Bet Works, $136B Stock Won't Move

Bristol Myers Squibb just pulled off something the FDA has never allowed before. On August 13, 2026, the agency granted accelerated approval to Zenbexus (iberdomide), the first CELMoD ever to reach the market, based on minimal residual disease negativity rather than progression-free survival. It is the first myeloma drug in history approved on that surrogate. BMY closed at $66.58 on August 28, giving the company a $136 billion market cap, and the stock has barely moved since the decision. That is the entire story in two sentences: a genuine scientific first, wrapped in a mega-cap balance sheet too big to care.

The question worth answering is not whether Zenbexus works. The approval already proved it works. The question is what this class is actually worth to BMY, and whether the successor math to Revlimid justifies owning the stock for it. The answer is the franchise is real and the stock move is not.

CELMoD versus IMiD: the cereblon difference

To understand why Zenbexus matters, you have to understand what separates a CELMoD from the IMiDs that came before it. Revlimid (lenalidomide) and Pomalyst (pomalidomide) are immunomodulatory drugs that bind a protein called cereblon, which sits inside an E3 ubiquitin ligase complex. Binding cereblon redirects that ligase to tag two transcription factors, Ikaros and Aiolos, for destruction. Killing Ikaros and Aiolos is what slows myeloma cell growth and revs up the immune system.

The catch is that lenalidomide and pomalidomide bind cereblon imprecisely. They degrade Ikaros and Aiolos, but they also degrade a scattering of other proteins, and they do it at doses high enough to cause the neutropenia and infections that make Revlimid hard to take. CELMoDs like iberdomide are engineered to grip cereblon tighter and degrade Ikaros and Aiolos more potently and more selectively. Same target, cleaner kill. That is why BMY is betting the class, not a single molecule.

The MRD precedent is the real prize

The approval rested on EXCALIBER-RRMM (NCT04975997), a Phase 3 trial that randomized 939 patients with relapsed or refractory myeloma. The MRD analysis covered the first 420 patients, split between Zenbexus plus daratumumab and dexamethasone (ZDd, n=207) and daratumumab, bortezomib, and dexamethasone (DVd, n=213). At a median follow-up of 16 months, ZDd drove an MRD-negative complete response in 41% of patients versus 21% for the control, a difference of 20 percentage points with p<0.0001.

MRD negativity means no detectable cancer cells at the most sensitive level of testing. In myeloma it is considered predictive of longer progression-free survival, which is why the FDA let BMY file on it. This is the first time the agency has accepted MRD-negative CR as the basis for an accelerated approval in this disease, and it changes the regulatory economics of the whole franchise. BMY can now run confirmatory trials on the PFS endpoint while the drug is already selling, rather than waiting years for PFS data before launch.

The tradeoff is real and it is the boxed warning. Neutropenia hit 90.2% of ZDd patients, with Grade 4 in 53.4%. Infections reached 78.9%, with fatal infections in 2%. Venous thromboembolism occurred in 6.4% and arterial events in 3.4% despite mandatory prophylaxis. The label carries boxed warnings for embryo-fetal toxicity and thromboembolism, and the drug ships only through a REMS program. This is not a clean profile. It is the price of a more potent cereblon degrader.

The approval is also provisional in a way investors underweight. Accelerated approval means BMY must still verify clinical benefit on progression-free survival, the dual primary endpoint that is still maturing inside EXCALIBER-RRMM. Full data are expected this year, and if the PFS read misses, the FDA can pull the indication. The MRD win bought BMY the launch; the PFS win is what keeps it.

The competitive ladder is crowded at the top

Where Zenbexus slots into the myeloma treatment sequence is the part that decides its commercial ceiling. The field is no longer Revlimid and nothing else. BCMA-directed therapies now dominate the late-line conversation: CAR-T versus bispecifics is the defining fight, with Carvykti and Abecma on the CAR-T side and Tecvayli and Talvey on the bispecific side. Gilead’s anito-cel BCMA CAR-T is moving toward its own approval. And Sanofi’s Sarclisa with the Escena on-body injector is pushing anti-CD38 therapy into earlier and easier lines.

Zenbexus sits earlier than all of these. It is approved as early as first relapse, where an oral triplet is a natural fit before patients are sick enough for CAR-T. That is the strategic bet: CELMoDs own the early-relapse oral segment the way Revlimid once owned frontline maintenance, while CAR-T and bispecifics fight over the later, sicker patients. It is a coherent position, but it means Zenbexus is not competing for the same high-price, high-margin late-line dollars as Carvykti.

Carvykti is the comp that matters in the room. Johnson & Johnson and Legend’s BCMA CAR-T is on a trajectory toward $5 billion-plus in annual sales, and it defines the depth-of-response bar Zenbexus will be measured against. An oral CELMoD triplet priced well below a CAR-T infusion has a real convenience argument, but it must clear a high bar in a population where depth of response now carries regulatory weight, not just clinical significance.

BMY’s own follow-on is the bigger near-term catalyst. Mezigdomide carries a PDUFA of May 13, 2027, backed by SUCCESSOR-2 data showing a median PFS of 18.0 months versus 8.3 months for carfilzomib and dexamethasone alone, a hazard ratio of 0.48 with p<0.0001. That is a cleaner efficacy story than Zenbexus’s MRD read, and it gives BMY two shots at the same CELMoD franchise.

The Revlimid math is why this is not a stock story

Here is where the successor thesis meets reality. Revlimid did $425 million in worldwide Q2 2026 revenue, down 49% year over year. Pomalyst did $204 million, down 71%. The Celgene-era myeloma franchise BMY paid $74 billion for in 2019 is in full generic retreat, and the Q2 earnings analysis already walked through the arithmetic: the Growth Portfolio is now 58% of revenue, but the Legacy Portfolio is the drag the market refuses to ignore.

Zenbexus and mezigdomide together rebuild part of that franchise, but they rebuild a fraction of it. Revlimid peaked near $12.8 billion a year. Two CELMoDs approved on MRD and PFS in relapsed myeloma are more likely to be $1 billion to $3 billion products than a clean replacement for a $12.8 billion drug. That is not a knock on the science. It is a statement about how big the hole is.

At $136 billion, BMY trades at roughly 2.6 times its guided 2026 revenue midpoint of $49.5 billion. Gilead trades at 3.2 times and Merck at 3.4 times. The discount is the 2028 Eliquis patent cliff plus the Opdivo biosimilar wave, and no CELMoD approval removes those overhangs. A class-first approval is a checkmark for the pipeline, not a re-rating event for the stock.

Verdict: the class is real, the trade is elsewhere

The CELMoD story is not the problem. The science is sound, the MRD precedent is a genuine regulatory advance, and BMY has a defensible two-drug strategy in a field already crowded with BCMA CAR-Ts, bispecifics, and CD38 antibodies. But BMY at $136 billion cannot move on a drug expected to add $1 billion to $3 billion in peak sales to a $49.5 billion revenue base. That is 2% to 6% of revenue at peak, and it arrives years from now.

If you want the CELMoD thesis to move your portfolio, BMY is the wrong vehicle for the same reason the approval scorecard flags every mega-cap catalyst: the catalyst is real, the stock impact is a rounding error. Hold BMY for the dividend and the Growth Portfolio execution, and buy the biotech pure plays for the catalyst exposure. The mezigdomide PDUFA in May 2027 is the next CELMoD date worth watching, and even that will not re-rate a $136 billion stock.

Source: FDA accelerated approval of iberdomide (August 13, 2026)